Summer Replay 4: Ezetimibe and clinical outcomes, BP lowering in diabetes and kidney disease

Subscribe on iTunes

Amol and Reena want you to understand the following:

1. When added to moderate dose statin, the IMPROVE-IT randomized trial showed that ezetimibe improved clinical outcomes in patients after acute coronary syndrome.

2. A network meta-analysis showed that no blood pressure lowering therapy improved mortality in patients with diabetes and chronic kidney disease. The combination of ACE-inhibitors and angiotensin receptor blockers was the most effective in preventing end-stage kidney disease.

The papers



Good Stuff



Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more